Skip to main content

Advertisement

Volume 9 Supplement 2

AIDS Vaccine 2012

HIV-1 subtype B- and F1-infected subjects display higher cross-clade T-Cell response than subtype C-infected subjects

Article metrics

  • 625 Accesses

Background

The impact of the extensive genetic diversity of the HIV-1 group M isolates and its implications for vaccine design have long been discussed. Studies indicate that Gag and Nef conserved epitopes are commonly recognized and give rise to high cross-clade responses. The aim of this study was to compare T-cell responses to peptide pools derivate from subtype B, C and F1 consensus, among Brazilian subjects infected with those three HIV-1 subtypes.

Methods

The study included 32 subjects infected with HIV-1 subtypes B (n=13), C (n=11) and F1 (n=8). Gag and Nef-specific T cell responses were evaluated by IFN-γ ELISpot assay, using peptide pools based on subtype B, C and F1 Brazilians consensus.

Results

A high cross-clade response between subtypes B and F1 for both Gag and Nef regions was observed among HIV-1 subtype B- and F1-infected subjects. We also found no significant difference in magnitude of responses between subtype B and C consensus peptides in subtype B-infected subjects.In contrast, the magnitude of T cell responses to consensus C peptides in Gag region was significantly higher than to consensus B peptides among HIV-1 subtype C-infected subjects. In Nef, subtype C-infected subjects showed higher T cell responses to C than to F1 consensus peptides. Moreover, subtype F1-infected subjects presented lower responses to subtype C peptides than to subtype F1 and B ones.

Conclusion

Overall, the level of cross-clade response between subtypes B and F1 was higher than between subtype C and B or between subtype C and F1. Our data suggest that significance of the HIV-1 group M genetic diversity for vaccine design may be dependent of the subtypes involved.

Author information

Correspondence to FH Côrtes.

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Keywords

  • Peptide
  • Genetic Diversity
  • Infectious Disease
  • Cancer Research
  • Cell Response